Cervical dystonia (CD) is the most common adult-onset isolated dystonia.^[@R1],[@R2]^ The percentage of patients with CD with head tremor, neuropsychiatric comorbidities, and spread of dystonia to other anatomical segments is mostly unknown in large multicenter clinical series. Genetic factors are believed to be important given that most large clinical series report a positive family history in approximately 10% of probands.^[@R3][@R4][@R5]^ Although sequence variants (SVs) in *THAP1*, *GNAL*, and Exon 5 of *TOR1A* have been identified in small percentages of participants with isolated CD, the relative contributions of dystonia-associated genes to mainly adult-onset (\>20 years)^[@R6]^ CD have not been fully characterized.^[@R3],[@R5],[@R7][@R8][@R14]^ In this study, we detail the clinical and genetic features of CD in a large multicenter cohort.

METHODS {#s1}
=======

Study design and patients. {#s1-1}
--------------------------

The Dystonia Coalition (DC, [www.rarediseasesnetwork.org/dystonia/](http://www.rarediseasesnetwork.org/dystonia/)) has developed a biospecimen repository (Coriell; Camden, NJ) and an associated clinical database to be used as a resource for dystonia research (<http://clinicaltrials.gov/show/NCT01373424>). Participants included in the analyses described herein were the first 1,000 with reported onset of dystonia in the nonlaryngeal, nonpharyngeal neck muscles. These participants were enrolled between January 5, 2011, and September 21, 2014. Data collection for the DC included the following: blood for the extraction of DNA and lymphocytes, Global Dystonia Rating Scale (GDRS), video examination, and clinical data elements (demographics, age at onset, site of onset, sensory tricks, anatomical distribution of dystonia, history of psychiatric disorders, and family history \[dystonia, parkinsonism, and tremor\]). Raters were also asked to indicate whether the neck was affected by tremor. The Dystonia Genetic Consortium is an international collaboration of neurologists interested in the genetics of dystonia and closely related neurogenetic disorders. Biological specimens acquired by the Dystonia Genetic Consortium are stored in the Department of Neurology at the University of Tennessee Health Science Center (UTHSC).

Standard protocol approvals, registrations, and patient consents. {#s1-2}
-----------------------------------------------------------------

The study was approved by the ethics committees of all participating centers. All participants gave written informed consent for participation in the study and inclusion in the biospecimen and video repositories.

Genetic screening. {#s1-3}
------------------

Because of the limited amounts of DNA available for this project (2 μg per participant) and questions related to the pathogenicity of *CIZ1* and *ANO3* SVs in participants with isolated dystonia, a combination of high-resolution melting (HRM) and Sanger sequencing was restricted to coding and contiguous noncoding regions of *THAP1*, *GNAL*, and Exon 5 of *TOR1A*.^[@R3],[@R5],[@R8],[@R10],[@R15]^ Exon 5 of *TOR1A* harbors the classic DYT1 ΔGAG mutation, and cosegregating pathogenic SVs have not been identified in other exons of *TOR1A*.^[@R7],[@R8],[@R15],[@R16]^ After the identification of 2 novel SVs in Exon 5 of *TOR1A*, an additional 1,160 DNA samples from the UTHSC Dystonia Genetics Consortium biorepository were also screened for these and other SVs within Exon 5 of *TOR1A* (table e-1 at [Neurology.org/ng](10.1212/NXG.0000000000000069)). Cases with known mutations in *TOR1A* and other dystonia-associated genes were excluded from this secondary screening effort.

In silico mutation prediction programs SIFT, MutationTaster, Polymorphism Phenotyping version 2 (PolyPhen-2), and Combined Annotation-Dependent Depletion (CADD) were used to evaluate the pathogenicity of novel and previously reported missense SVs.^[@R17][@R18][@R20]^ TargetScanHuman 6.2 ([www.targetscan.org](http://www.targetscan.org)) was used to search for predicted microRNA (miRNA) targets within loci harboring SVs.^[@R21]^ Human Splicing Finder 3.0 ([www.umd.be/HSF](http://www.umd.be/HSF)) was used to predict the effects of identified SVs on splicing motifs including acceptor and donor splice sites, and branch point and auxiliary sequences known to either enhance (exonic splicing enhancers \[ESEs\]) or repress (exonic splicing silencers \[ESSs\]) splicing.^[@R22]^ The allele frequency of the identified SVs was compared with the frequencies reported in Exome Variant Server (EVS, [evs.gs.washington.edu/EVS/](http://evs.gs.washington.edu/EVS/)), 1000 Genomes Project (1KG, [www.1000genomes.org](http://www.1000genomes.org)), and Exome Aggregation Consortium (ExAC, [exac.broadinstitute.org](http://exac.broadinstitute.org)). American College of Medical Genetics and Genomics guidelines were used for the classification of SVs as "pathogenic," "likely pathogenic," "uncertain significance," "likely benign," or "benign."^[@R23]^ Details of HRM, Sanger sequencing, and variant analysis are included in appendix e-1 and table e-2.

Statistical analysis. {#s1-4}
---------------------

Fisher exact tests (2-tailed) were used to compare female-male frequencies. The χ^2^ statistic (2-tailed) was used to compare case-control genotype frequencies. Two-tailed *t* tests were used to determine whether age, age at onset, duration, and scores on rating scales differed between women and men. The Pearson correlation coefficient (*r*) was used to measure the strength of linear associations between GDRS scores and number of affected anatomical segments, dystonia duration, and dystonia age at onset. An alpha (α) of 0.05 was chosen for statistical significance.

RESULTS {#s2}
=======

The majority (95%) of participants were Caucasian females ([table 1](#T1){ref-type="table"}). The mean age at onset and disease duration for the entire cohort of 1,000 participants were 45.5 and 14.6 years, respectively. A high percentage of the 1,000 participants with CD had a head tremor (62%), and head tremor was more common in females than in males. Total GDRS scores did not differ between males and females. The majority of participants (68.5%) had anatomical involvement limited to the neck ± shoulder(s) and proximal arm(s). Less than half of the patients enrolled in this cohort were judged to have isolated neck involvement (47.4%). Females with CD were more likely to manifest laryngeal dystonia. Otherwise, there were no significant effects of sex on patterns of anatomical involvement. Age at onset decreased with the number of affected anatomical segments and GDRS total score ([table 2](#T2){ref-type="table"}). Dystonia duration increased with the number of affected anatomical segments and GDRS total score.

###### 

Clinical features of the study population
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###### 

Effect of age at onset and disease duration on distribution and severity of dystonia
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The majority of participants reported at least 1 sensory trick (71%), which did not differ between males and females. Psychiatric disorders were reported more commonly by females (35%) than males (23%) and included, in the order of frequency, isolated depression, combined anxiety and depression, and isolated anxiety. Although myoclonus (2%) and parkinsonism (1%) were reported in small numbers of participants, etiologic diagnosis was not part of the study protocol.

A family history of dystonia was reported by 14% of the participants ([table 1](#T1){ref-type="table"}). Among the participants with a family history, 2 participants reported that both their mother and father were affected, whereas 46 reported an affected mother and 27 reported an affected father. A family history of parkinsonism was reported by 11%. Parkinsonism was reported more commonly by females (13%) than males (7%). Overall, 29% of participants reported a family history of tremor and there was no significant difference between females (30%) and males (24%). The presence or absence of dystonia, parkinsonism, and tremor in family members was not confirmed by face-to-face examinations or telephone interviews.

Twelve coding SVs ([tables 3 and 4](#T3 T4){ref-type="table"}, [figure](#F1){ref-type="fig"}) predicted to be possibly pathogenic or deleterious by at least 1 of 4 (SIFT, MutationTaster, PolyPhen-2, and CADD) in silico prediction programs were identified in our cohort. In addition, the classic ΔGAG deletion mutation in *TOR1A* was identified in 1 participant ([tables 3 and 4](#T3 T4){ref-type="table"}).

###### 

Bioinformatic analysis of SVs identified in participants with CD
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###### 

Clinical features of probands harboring missense or indel SVs in coding regions
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![Pedigrees of probands with missense sequence variants in *GNAL*, *THAP1*, and *TOR1A*\
Arrows = probands; filled symbols = affected; half-filled symbols = possibly affected.](NG2016002071FF1){#F1}

A definite family history of CD was reported by a single proband with a *GNAL* SV (DYS87, p.V354M). The mother of DYS87 ([figure](#F1){ref-type="fig"}, II-A) had CD with age at onset of 43 years. Family history was inconclusive in another *GNAL* pedigree (DYS497). The mother of DYS497 ([figure](#F1){ref-type="fig"}, I-A) had a low-frequency right-hand tremor with onset in her late 60s, approximately 5 years after an apparent episode of tardive dyskinesias due to neuroleptic medication treatment of a psychiatric disorder. Reportedly, the tremor did not improve with medical treatment. Gait was shuffling and hand writing was tremulous but not micrographic. Participant I-A from pedigree DYS497 was never formally diagnosed with drug-induced parkinsonism, Parkinson disease, or SWEDDs (scans without evidence of dopaminergic deficit).

Family histories of tremor were reported by 2 probands with *TOR1A* missense SVs ([figure](#F1){ref-type="fig"}). The father of DYS266 had a late adult-onset tremor of historically unreliable anatomical distribution. The brother of DYS1565 was treated with deep brain stimulation for severe head and arm tremors. Two sisters (II-B and II-E) also had head tremors. Of note, participants I-A, II-B, and II-D had onset of tremor in their 40s and all 3 died of cancer, whereas participant II-E died after an automobile accident.

Among coding SVs, the *THAP1* p.S51R SV had the highest CADD Phred score (27.1) and showed relatively high penetrance with multiple affected individuals in the pedigree ([figure](#F1){ref-type="fig"}). The proband\'s sister ([figure](#F1){ref-type="fig"}, III-D), also enrolled in the DC biorepository, harbors the same p.S51R SV but had initial onset in the distal arm-hand anatomical segment at 32 years of age that has now progressed to generalized dystonia. One of her 2 daughters (IV-F) has generalized dystonia with onset in the distal arm-hand at 7 years of age, and a granddaughter (V-I) has CD and possible lower extremity dystonia with onset at 15 years of age. Participant IV-E had onset of dystonia in the neck and shoulder in her mid-20s with spread to the right distal arm and hand by her early 30s. Participant IV-E is now 43 years old and has generalized dystonia with additional involvement of her left arm and leg. Her daughter, participant V-H, had onset of right-arm dystonia at 13 years of age. Participant III-B has spasmodic dysphonia and participant V-G has dystonia of unknown anatomical distribution.

Synonymous SVs were identified in *GNAL* (p.R22R, p.A338A) and *THAP1* (p.P19P). The *GNAL* R22R SV was found in ExAC, 1KG, and EVS, and in 6 participants within the DC. *GNAL* R22R was not enriched in the DC cohort. However, the R22R variant had a CADD Phred score of 22.1 and is predicted to break an ESE site. *GNAL* A338A was identified in 33 patients in the DC cohort, all heterozygotes. In comparison with ExAC, *GNAL* A338A was enriched in the DC cohort (χ^2^ = 13.034, *p* = 0.0003). Moreover, this variant is predicted to be disease causing by MutationTaster and has a CADD Phred score of 19.2 and may generate a new ESS site. *THAP1* P19P is categorized as disease causing by MutationTaster and was found in 1 participant in the DC cohort.

Noncoding SVs were identified in *GNAL* and *THAP1*. A c.218+19C\>A SV in *GNAL* is predicted to be marginally deleterious by CADD but is found at high frequency within the ExAC database. The c.932-7T\>G SV in *GNAL* is frequent in the DC, ExAC, and 1KG databases and benign ([table 3](#T3){ref-type="table"}). None of the coding or noncoding variants detected in this study are predicted to disrupt miRNA-binding domains.

Follow-up screening of *TOR1A* Exon 5 identified 3 patients with the classic DYT1 ΔGAG deletion (table e-1).^[@R7],[@R8]^ In addition, 1 participant (DYS_85085, [figure](#F1){ref-type="fig"}) was found to have the same c.962C\>T (p.T321M) SV as DC DYS1565. DYS_85085 was initially evaluated at 53 years of age for mild gait dysfunction and found to have mild spasticity with bilateral Babinski responses and hyperreflexia of undetermined etiology. Despite mild foot drop, she was able to walk unaided at 66 years of age. At 59 years of age, she developed abnormal head posturing with subsequent spread of dystonia to her arms, worse in the left arm than in the right. On the most recent examination, she had CD with an irregular/jerky head tremor, along with bilateral arm tremors. Her deceased brother and father had a similar gait abnormality. DNA acquired from an alive and neurologically normal brother did not harbor the c.962C\>T SV. The proband\'s deceased mother and maternal grandmother had jerky head tremors but normal gait.

DISCUSSION {#s3}
==========

We characterized the clinical features of CD and contributions of known isolated dystonia-associated genes to the etiopathogenesis of CD and established a platform for future clinical and genetic studies of dystonia. The demographics of our cohort are compatible with the previous epidemiologic studies of CD and other forms of dystonia.^[@R24]^ In particular, CD is more common in females than in males and, apparently, less common in African Americans than in Caucasians.^[@R1],[@R25]^ Women with CD were more likely than men to exhibit a head tremor, develop laryngeal dystonia, and report a history of at least the onset of a psychiatric disorder. However, the effect of sex on the frequencies of psychiatric conditions should be interpreted with caution given that we did not use a control cohort for the nongenetic aspects of our study.

As suggested by our data set, the boundaries between focal and segmental dystonia and definition of CD are often imprecise.^[@R26]^ In the neck, for example, the trapezius and levator scapulae muscles insert on the scapula and cross the neck and shoulder anatomical regions. In our study, only 47% of participants were deemed to exhibit isolated neck involvement, whereas 69% were reported to manifest dystonia in the neck and shoulder(s). The current classification of dystonia states that CD is "considered a form of focal dystonia, although by convention the shoulder can be included as well as the neck."^[@R6]^

Small percentages of participants were reported to have had myoclonus (2%) or parkinsonism (1%). Because of the limiting quantities of DNA available for this study, participants with myoclonus were not screened for mutations in *SGCE*, *KCTD17*, *RELN*, or *CACNA1B*. In addition, neurophysiologic studies were not performed to differentiate myoclonic from dystonic jerks and we did not formally diagnose the cause of parkinsonism in this small group of 10 patients or differentiate dystonic from nondystonic causes of SWEDDs.^[@R27]^

In our cohort, a considerable majority of participants had a head tremor. The presence of tremor in dystonia and dystonia in patients with various forms of tremor including essential tremor or "isolated tremor" has received increasing attention in the recent medical literature.^[@R28],[@R29]^ The presence of either dystonia or isolated tremor in individuals within some pedigrees suggests that subtypes of isolated tremor may exist and share genetic etiologies with some forms of dystonia.^[@R30]^ Of note, the high family history of tremor (29%) in our cohort exceeded the combined family histories of parkinsonism and dystonia.

A role for genetic factors in the etiopathogenesis of CD has long been recognized.^[@R31],[@R32]^ In a review of 266 patients with isolated CD from a single center, 12% had a positive family history of dystonia.^[@R32]^ Similar percentages of participants with first- or second-degree relatives with dystonia have been reported in large genetic screening studies of CD and other isolated dystonia cohorts.^[@R3],[@R4],[@R10]^ Therefore, the 14% of CD participants with a positive family history of dystonia is in line with the previous works.

A small but noteworthy percentage (11%) of participants in our CD cohort reported a positive family history of parkinsonism. In this regard, postmortem pathologic studies and animal models of dystonia suggest that mild damage to the dopaminergic nigrostriatal pathway may contribute to the pathogenesis of dystonia.^[@R33],[@R34]^ However, isolated dystonia has not been shown to be a risk factor for Parkinson disease and vice versa, and family members were not accessible for neurologic examinations to diagnose SWEDDs, Parkinson disease, or other parkinsonian disorders.

Generally, the genetic contributions to CD identified in this study were small; patients with pathogenic or likely pathogenic missense SVs tended to show evidence of spread to contiguous anatomical segments over time, and among those genes interrogated, *GNAL* had the largest impact ([tables 3 and 4](#T3 T4){ref-type="table"}). We identified several pathogenic or likely pathogenic *GNAL* missense variants in our cohort.^[@R23]^ Likely due to the focus on CD, the frequency of missense variants in *GNAL* reported herein was modestly higher than that reported in other screening studies.^[@R5],[@R35]^ Perhaps most importantly, a synonymous variant of uncertain significance (p.A338A) was enriched in our CD cohort in comparison with the population controls contained in the ExAC database. Accordingly, A338A may increase the risk of developing CD.

Not unexpectedly, SVs in *THAP1* were infrequent in our CD cohort. In previous screening studies, pathogenic or likely pathogenic *THAP1* missense SVs were found in less than 1% of the patients with mainly adult-onset isolated dystonia.^[@R10],[@R11]^ The synonymous *THAP1* variant (p.P19P) identified in 1 participant in our cohort was previously reported in a patient with segmental craniocervical dystonia.^[@R10]^ The c.71+9C\>A intronic variant was found in 1 participant in this study and previously reported as enriched in patients with dystonia in comparison with neurologically normal controls.^[@R36]^

Notably, our screening efforts exposed a non-ΔGAG SV in *TOR1A* (c.962C\>T, p.T321M) in 2 pedigrees from different regions of the United States. Family history information acquired from the probands suggested that these pedigrees were unrelated. We also identified another SV in *TOR1A* (c.823A\>G, p.K275E) of uncertain significance. Other *TOR1A* variants of uncertain significance have been described in single individuals with dystonia.^[@R37],[@R38]^ Both p.K275E and p.T321M are contained at very low frequencies within the ExAC database, and all 3 probands harboring these *TOR1A* SVs reported a positive family history of dystonia. Studies of p.K275E and p.T321M torsinA in cellular systems and animal models should provide important and novel insights into the biology of dystonia. The classic *TOR1A* ΔGAG mutation is infrequent (2/1,319 patients = 0.15%) in participants with dystonia onset in the neck.

Given that our screenings were limited to *THAP1*, *GNAL*, and Exon 5 of *TOR1A*, the potential roles of *CIZ1*, *ANO3*, and Exons 1, 2, 3, and 4 of *TOR1A* in the pathogenesis of CD remain uncertain. In addition, we did not interrogate promoter and deep intronic regions for variants of possible pathogenic significance and cannot exclude the possibility that some participants in our cohort harbored large deletion mutations in these or other dystonia-associated genes. Conversely, those missense and noncoding variants reported herein were not subjected to cosegregation analyses or downstream molecular and cellular assays of deleteriousness.

Our data set provides a comprehensive presentation of CD phenotypes and rational overview of CD genetics. The majority of patients with CD have a head tremor and an important percentage exhibit spread to contiguous anatomical regions, have personal histories of psychiatric disorders, and have family histories of tremor and dystonia. Although coding and noncoding SVs in *GNAL*, *THAP1*, and *TOR1A* contribute to the development of CD, the yield of clinical genetic testing for pathogenic SVs in this collection of genes will be low in sporadic cases of CD, particularly in those participants without any evidence of spread to other anatomical segments, but may be considered in individuals from multiplex pedigrees with dystonia. The prevalence of pathogenic and likely pathogenic SVs in dystonia-associated genes reported herein should be considered a minimum because we did not exclude copy number variants or include *GCH1*, *SGCE*, *KCTD17*, *RELN*, *CACNA1B*, *HPCA*, and *TAF1* in our screenings. Clinical genetic testing of *TOR1A* in patients with dystonia should not be limited to discovery of the classic ΔGAG mutation given that other *TOR1A* SVs may be pathogenic. Future studies into the molecular and cellular biology of CD should benefit from the identification of other genetic etiologies and must consider potential biological commonalities with Parkinson disease, isolated tremor, and psychiatric disorders, principally depression and anxiety.
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